Souhaitez-vous accéder aux communiqués récents ?

- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q2 2023 year-over-year revenue growth...

- Company to host conference call and webcast on Thursday, August 24th at 8:30 am EDT - LYON, France, August 10, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based...

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in...

LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled...

- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17that 8:30 am...

- Company to host conference call and webcast on Wednesday, May 17that 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic...

  Meeting to Showcase EDAP’s Focal One® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq:...

Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP...

Allows for market launch of the only micro-ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in...

Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as...